Table 1.
The characteristics of the 16 patients with CML.
| Patient number | Disease status | Gender | Age | WBC count (×109/L) | Karyotype | Anti-CML therapy |
|---|---|---|---|---|---|---|
| 1 | Chronic phase | M | 60 | 138.5 | t(9;22)(q34;q11) | None |
| 2 | Chronic phase | M | 54 | 75.6 | Complex | None |
| 3 | Accelerated phase | F | 49 | 105.2 | t(9;22)(q34;q11) | None |
| 4 | Chronic phase | F | 51 | 46.3 | t(9;22)(q34;q11) | None |
| 5 | Chronic phase | M | 53 | 237.9 | t(9;22)(q34;q11) | None |
| 6 | Accelerated phase | F | 64 | 392.3 | t(9;22)(q34;q11) | None |
| 7 | Accelerated phase | F | 47 | 153.4 | t(9;22)(q34;q11) | None |
| 8 | Blastic crisis | F | 55 | 242.7 | t(9;22)(q34;q11) | None |
| 9 | Blastic crisis | M | 58 | 175.8 | Complex | None |
| 10 | Chronic phase | M | 39 | 409.1 | t(9;22)(q34;q11) | None |
| 11 | Chronic phase | M | 47 | 364.5 | t(9;22)(q34;q11) | None |
| 12 | Chronic phase | F | 62 | 283.4 | t(9;22)(q34;q11) | None |
| 13 | Accelerated phase | M | 60 | 196.7 | t(9;22)(q34;q11) | None |
| 14 | Accelerated phase | F | 44 | 83.5 | t(9;22)(q34;q11) | None |
| 15 | Chronic phase | M | 45 | 252.4 | Complex | None |
| 16 | Chronic phase | M | 47 | 375.9 | t(9;22)(q34;q11) | None |